Hematologic malignancies are one of the most common cancers, and the incidence has
been rising in recent decades. The clinical and molecular features of hematologic …

Histone deacetylases (HDACs) are epigenetic enzymes which participate in transcriptional
repression and chromatin condensation mechanisms by removing the acetyl moiety from …

Bone marrow transplantation is regarded as the most effective immunotherapy for
hematologic cancer, but it generally faces difficulties in matching. Aberrant expression of …

HDAC6, a member of the histone deacetylase family, mainly is a cytosolic protein and
regulates cell growth by acting on non-histone substrates, such as α-tubulin, cortactin, heat …

Leukemia cells prevent immune system from clearing tumor cells by inducing the
immunosuppression of the bone marrow (BM) microenvironment. In recent years, further …

Simple Summary Nowadays, many patients with chronic lymphocytic leukemia (CLL) are
treated with so-called novel agents, including BTK inhibitors, Bcl-2 inhibitors and PI3K …

Abstract Indoleamine 2.3-dioxygenases (IDO1/2) and tryptophan 2.3-dioxygenase (TDO) are
the initial and rate-limiting enzymes in tryptophan metabolism, which play an essential role …

The search for effective combination therapy with immune checkpoint inhibitors (ICI) has
become important for cancer patients who do not respond to the ICI well. Histone …

Histone deacetylases (HDACs) are promising targets for the design of anticancer drugs.
HDAC6 is of particular interest since it is a cytoplasmic HDAC regulating the acetylation …

Chronic lymphocytic leukemia (CLL) is characterized by widespread alterations in the
genetic and epigenetic landscapes which seem to underlie the variable clinical …